Physician profile
Mark Bartruff
NPI 1831712173
$4,186.91
in general payments reported to CMS, 2019-2025
19 companies · $775 in 2025
The $775 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $776 · 2022: $515 · 2023: $1,223 · 2024: $898 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,896.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,836.94 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $210.87 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $193.16 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.01 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $131.80 | 2021-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $110.59 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $101.63 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $89.23 | 2022-2024 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $87.54 | 2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $86.01 | 2024 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $43.20 | 2023 | Wellbutrin, Aplenzin |
| Noven Therapeutics, LLC | $29.71 | 2023-2024 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $28.42 | 2024-2025 | Qelbree |
| Corium, LLC | $18.54 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $18.07 | 2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.62 | 2025 | Cobenfy |
| Tris Pharma INC | $14.14 | 2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.69 | 2025 | Trintellix |
| Alfasigma USA, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bartruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.